Long-term immunoprophylaxis of hepatitis B surface antigen carrier in infants born to hepatitis B surface antigen positive mothers using plasma derived vaccine.
Immunoprophylaxis of HBV infection using 3 doses (10 micrograms) of plasma derived HBV vaccine were given to 49 newborn infants of e-antigen negative HBs Ag carrier mothers at birth, one and 6 months of age. The protective efficacy rate was 100% during first 2 years. At 3 years of age, HBs Ag carrier was 2.63% and 89.48% of infants had anti-HBs above the protective level. Ten point fifty-two percent of total infants had anti-HBs level below 10 mIU/ml and 21.05% had anti-HBs level between 10-100 mIU/ml. Most infants who had the maximal level of antibody below 100 mIU/ml had lost all antibody within 3 years. The loss of antibody was closely related to the maximal anti-HBs titer (one year of age) which is highly predictive indicator of the longevity of anti-HBs.
Theppisai
U
U
Thanuntaseth
C
C
Chiewsilp
P
P
Siripoonya
P
P
D000914:Antibodies, Viral / Q000032:analysis; D002353:Carrier State; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D014761:Viral Hepatitis Vaccines
D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines